BridgeBio Pharma (BBIO) Current Deferred Revenue (2019 - 2026)

BridgeBio Pharma's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 47.38% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 47.38% YoY), while the FY2025 annual figure was $7.2 million, down 50.77% from the prior year.
• Current Deferred Revenue came in at $6.1 million for Q1 2026 at BridgeBio Pharma, down from $7.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $100.0 million in Q2 2024 to a low of $6.1 million in Q4 2023.
• A 5-year average of $20.5 million and a median of $9.8 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue sank 93.1% in 2023 and surged 1510.31% in 2024, its largest moves.
• BridgeBio Pharma's Current Deferred Revenue stood at $19.8 million in 2022, then slumped by 69.21% to $6.1 million in 2023, then jumped by 139.57% to $14.6 million in 2024, then sank by 50.77% to $7.2 million in 2025, then dropped by 14.95% to $6.1 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.1 million, $7.2 million, and $9.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison